Source:http://linkedlifedata.com/resource/pubmed/id/20062090
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
9
|
pubmed:dateCreated |
2010-9-8
|
pubmed:abstractText |
Acute GVHD has remained a significant cause of nonrelapse mortality after allogeneic hematopoietic cell transplantation (HCT) with nonmyeloablative conditioning. The role of TNF-alpha in the biology of acute GVHD after nonmyeloablative conditioning has not been studied thus far. Here, we measured TNF receptor 1 (TNFR1) as a surrogate marker for TNF-alpha in 106 patients before the start of the conditioning regimen (baseline) and 7 days after allogeneic HCT with nonmyeloablative conditioning. The nonmyeloablative regimen consisted of 2 Gy TBI alone (n=15), 2 Gy TBI plus fludarabine 90 mg/m2 (n=73), or 4 Gy TBI plus fludarabine 90 mg/m2 (n=18). TNFR1 levels increased significantly from baseline to day 7 after nonmyeloablative HCT (P<0.0001). Patients conditioned with 4 Gy TBI had higher TNFR1 day 7/baseline ratio than those conditioned with 2 Gy TBI (median 1.65 versus 1.25; P=0.01). In a multivariate Cox model, high TNFR1 day7/baseline ratio was associated with grades II-IV (HR=2.2, P=0.01) and grades III-IV (HR=2.9, P=0.007) acute GVHD, but had no impact on overall survival (P=0.8). In summary, our data suggest that nonmyeloablative conditioning induces the generation of TNF-alpha, and that the magnitude of TNF-alpha generation depends on the conditioning intensity (2 Gy versus 4 Gy TBI). Further, assessment of TNFR1 levels before and on day 7 after nonmyeloablative HCT provided useful information on subsequent risk of experiencing acute GVHD.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
1476-5365
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
45
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1442-8
|
pubmed:meshHeading |
pubmed-meshheading:20062090-Acute Disease,
pubmed-meshheading:20062090-Adolescent,
pubmed-meshheading:20062090-Adult,
pubmed-meshheading:20062090-Aged,
pubmed-meshheading:20062090-Child,
pubmed-meshheading:20062090-Cohort Studies,
pubmed-meshheading:20062090-Female,
pubmed-meshheading:20062090-Graft vs Host Disease,
pubmed-meshheading:20062090-Hematologic Diseases,
pubmed-meshheading:20062090-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:20062090-Humans,
pubmed-meshheading:20062090-Male,
pubmed-meshheading:20062090-Middle Aged,
pubmed-meshheading:20062090-Receptors, Tumor Necrosis Factor, Type I,
pubmed-meshheading:20062090-Recurrence,
pubmed-meshheading:20062090-Ribosomal Proteins,
pubmed-meshheading:20062090-Risk Factors,
pubmed-meshheading:20062090-Transplantation, Homologous,
pubmed-meshheading:20062090-Transplantation Chimera,
pubmed-meshheading:20062090-Transplantation Conditioning,
pubmed-meshheading:20062090-Young Adult
|
pubmed:year |
2010
|
pubmed:articleTitle |
Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
|
pubmed:affiliation |
Division of Hematology, Department of Medicine, CHU of Liége, Liége, Belgium.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|